Skip to main content
Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
4.840
-0.120 (-2.42%)
At close: Apr 28, 2026, 4:00 PM EDT
4.940
+0.100 (2.07%)
Pre-market: Apr 29, 2026, 5:45 AM EDT

Niagen Bioscience Revenue

In the year 2025, Niagen Bioscience had annual revenue of $129.42M with 29.95% growth. Niagen Bioscience had revenue of $33.84M in the quarter ending December 31, 2025, with 16.19% growth.

Revenue (ttm)
$129.42M
Revenue Growth
+29.95%
P/S Ratio
3.00
Revenue / Employee
$1,106,179
Employees
117
Market Cap
388.40M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025129.42M29.83M29.95%
Dec 31, 202499.60M16.03M19.18%
Dec 31, 202383.57M11.52M15.99%
Dec 31, 202272.05M4.60M6.82%
Dec 31, 202167.45M8.19M13.82%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 30, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Puma Biotechnology 228.37M
Century Therapeutics 109.16M
Autolus Therapeutics 75.39M
Enanta Pharmaceuticals 66.98M
Invivyd 53.43M
Lineage Cell Therapeutics 14.56M
Armata Pharmaceuticals 4.90M
YD Bio 510.36K
Revenue Rankings

NAGE News

More News